Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • thirdmeinvestor thirdmeinvestor Jul 10, 2006 1:08 PM Flag

    siRNA vs. Vaccines against Pandemic Flu

    An intrinsic limitation of the efficacy of any vaccine is its reliance on the immune status of the recipient. Elderly patients, in particular, frequently fail to mount effective responses following vaccination. Therefore, in addition to vaccination, there are drugs approved for use against IAV. The available drugs have two distinct modes of action. Amatadine and rimantadine block the M2-ion channel, preventing IAV penetration into host cells. Zanamivir and oseltamivir are neuraminidase inhibitors that block the release of IAV particles from sialic acid residues on mucus, serum proteins and cell surfaces. These drugs can prevent IAV infection if provided prophylactically and can reduce the duration of symptoms by one day if given within the first day of illness. Drug activity is not subtype specific, but the usefulness of the ion-channel blockers is restricted by the relatively rapid emergence of drug-resistant variants. Furthermore, expense, potential side effects and the timing of delivery for maximum benefit have limited the use these drugs to high-risk populations.
    The need for novel strategies for the prevention and treatment of IAV infection is evident given the limitations of available anti-IAV strategies. In the United States, an average of 20 000 deaths are annually attributed to IAV, despite the availability of vaccines and drugs. Worldwide, the toll is estimated at up to half a million deaths per year. The greatest danger to humanity would be the emergence of a novel pandemic strain that is not covered by existing vaccines. The past few years have seen emergence of highly pathogenic avian strains that threaten to become transmissible in humans through recombination and mutation in animal hosts.
    siRNA: a promising new approach to anti-influenza therapy
    Ge et al. and Tompkins et al. provide remarkable experimental evidence in mice that short interfering RNAs (siRNAs) might ultimately provide a solution to the variability of the IAV HA. These studies convincingly demonstrate that siRNAs, and the similarly functioning small-hairpin RNAs (shRNAs), expressed by a lentivirus DNA vector can prevent and treat IAV pneumonia in mice. There were reductions in lung virus titers or lethality, or both, using siRNAs specific for conserved regions of the IAV nucleoprotein (NP), acid polymerase (PA) and basic polymerase 1 (PB1), whether administered prior or subsequent to the virus challenge. The results of Tomkins et al. impressively showed protection against a lethal challenge with the highly pathogenic H5N1 and H7N7 IAV strains. Although not yet demonstrated experimentally, a potential advantage over vaccines is that siRNAs might not require an intact immune system.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • siRNA: a promising new approach to anti-influenza therapy

      <The what and how of siRNAs>

      siRNAs are 21�25-nucleotide RNAs that act posttranscriptionally to induce homologous sequence-dependent degradation of mRNAs. The native process of sequence-specific silencing involves long double-stranded RNAs (dsRNAs). Long dsRNAs are processed in the cell by the dsRNA-specific endonuclease DICER, which cleaves the targeting dsRNAs into 21�25-nucleotide fragments. The double-stranded siRNAs associate with the RNA-interference silencing ribonucleoprotein complex (RISC). The RISC contains adaptor proteins that bind to the siRNAs and unwind them (helicase activity) to generate single-stranded siRNAs. Another protein in the RISC, Argonaute 2, has RNase or SLICER activity. It cleaves the targeted RNAs (in this case the influenza virus RNA).

      For targeted gene silencing, synthetic short double-stranded siRNAs are transfected into cells. A simplified schematic of siRNA-mediated degradation of influenza virus RNA is shown in
      [[Figure 1. Short-interfering RNA (siRNA)-mediated degradation of influenza polymerase (PA) RNA. To target specific RNAs for degradation, such as influenza PA, complementary synthetic short double-stranded siRNAs are transfected into cells. The double-stranded siRNAs are bound by RNA-interference silencing ribonucleoprotein complexes (RISCs). A helicase protein within the RISCs unwinds the two strands and generates single-stranded siRNAs. The single-stranded antisense siRNAs then bind to complementary influenza PA RNAs and guide SLICER (Argonaute 2) to specifically cleave the influenza PA RNAs at the site of siRNA binding.]].

      The synthetic short double-stranded siRNAs do not require the DICER activity that is necessary for the processing of long dsRNAs. Long dsRNAs are found in virus-infected cells, but generally not in normal eukaryotic cells. The problem with using long dsRNAs is that they activate the interferon (IFN) system and the dsRNA-dependent IFN-inducible protein kinase (PKR). This leads to effects on cytokine signaling and transcription, the degradation of mRNA, the inhibition of translation and cell death. To avoid the adverse effects of long dsRNAs, viruses have evolved dsRNA binding proteins that can inhibit the effects of IFN and antiviral RNA interference. What makes short double-stranded siRNAs more useful for targeted gene silencing is that they induce the homologous sequence-dependent degradation of mRNAs without activating the IFN system. As with the in vivo impact of duplexed siRNAs against IAV observed by Ge et al. and Tompkins et al., the sequence specificity and virus specificity further control for potential IFN induction by dsRNAs and demonstrate that the antiviral effects are not due to IFN.
      siRNAs have been touted as a panacea for a wide range of applications. They have become standard in vitro laboratory tools to block specific gene activity, through the degradation of mRNAs, to inhibit virus replication. Recent reviews emphasize that the use of siRNAs holds great promise not only for combating viruses and other human pathogens but also allergies, tumors, pain and neurological diseases.

 
ALNY
119.870.00(0.00%)Jun 30 4:00 PMEDT